Novartis delivered growth on top and bottom line in all divisions in Q3
(WorldNews Switzerland)

Net sales grew 2% (cc[1], +2% USD), with growth in all divisions: Cosentyx (USD 556 million, +83% cc) showed strong growth across all indications Entresto (USD 128 million, +138% cc) grew driven by improved access and US sales force expansion Excluding Gleevec/Glivec, Oncology grew 11% (cc) Alcon was up 7%[2] (cc) with strong growth in Surgical and continued growth in Vision Care Sandoz grew 1% (cc) driven by growth outside the US, fully offsetting US price pressure Net income grew 10% (cc, +7% USD) Core[1] operating income grew 1% (cc, 0% USD) as growth drivers and productivity offset generic erosion of Gleevec/Glivec: Core EPS of USD 1.29, grew 6% (cc, +5% USD) Free cash flow[1] grew 18%...